Research | Clinical Trials

Research | Clinical Trials 2018-11-08T15:14:01+00:00

Protocol INCAGN 2385-101

Protocol INCAGN 2385-101

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

Sponsor: InCyte Biosciences Internationals Sarl

Status: Active, enrolling

Protocol M16-312

Protocol M16-312

An Open Label, Phase 1 Study of SC-006 as a Single Agent and in Combination with ABBV-181 in Subjects with Advanced Colorectal Cancer

Sponsor: AbbVie

Status: Upcoming

Protocol MGD007-02

Protocol MGD007-02

A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma

Sponsor: MacroGenics

Status: Upcoming

Protocol CPI-006-001

Protocol CPI-006-001

A Phase 1/1b multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with Pembrolizumab in adult subjects with advanced cancers.
Sponsor: Corvus Pharmaceuticals

Status: Active, enrolling
https://www.clinicaltrials.gov/ct2/show/NCT03454451